局部区域既往放疗后头颈癌挽救治疗的成本效果分析
本研究用 Markov 模型评估 5 种复发头颈癌挽救治疗策略的成本效果,临床参数取自文献综述与 2016 年 Medicare 报销数据,以每获得 1 个 QALY 支付 10 万美元为意愿支付阈值。
要点
- 基础分析中 5 种挽救策略在 10 万美元/QALY 阈值下均不具成本效果。
- SBRT 单用中位生存≥11 个月时被认为具成本效果。
核心结论
- 在 10 万美元/QALY 的意愿支付阈值下,5 种挽救治疗策略均不具成本效果。
- 基于 SBRT 的再放疗有潜力具备成本效果。
研究设计与样本
- 建立 Markov 模型,比较 5 种挽救治疗策略:铂类化疗单用、化疗联合西妥昔单抗、SBRT 单用、SBRT 联合西妥昔单抗、IMRT 联合化疗。
- 临床参数来自综合文献综述与 2016 年 Medicare 报销数据。
- 以 ICER 比较策略,效果指标为 QALY,意愿支付阈值为每 QALY 10 万美元。
主要发现
- 基础病例分析中,没有治疗策略在意愿支付阈值下具成本效果。
关键数值与推荐
- 意愿支付阈值为每 QALY 10 万美元。
- 若 SBRT 单用的中位生存期≥11 个月,则 SBRT 被认为具成本效果。
临床怎么用
- 复发且既往放疗的头颈癌选择挽救方案时,可结合成本效果考量。
- SBRT 单用可作为有成本效果潜力的再放疗选择,但需满足中位生存≥11 个月的条件。
局限性
- 临床参数来源于文献综述与 2016 年 Medicare 报销数据,成本数据具时效与地区局限。
- 结论基于 Markov 模型假设,结果受模型参数与意愿支付阈值设定影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The purpose of this study was to present our evaluation of the cost-effectiveness of salvage therapies for patients with recurrent head and neck cancer. METHODS: A Markov model was developed with 5 salvage treatment strategies: (1) platinum-based chemotherapy alone; (2) chemotherapy plus cetuximab; (3) stereotactic body radiotherapy (SBRT) alone; (4) SBRT plus cetuximab; and (5) intensity-modulated radiotherapy (IMRT) plus chemotherapy. Clinical parameters were obtained from comprehensive literature review and 2016 Medicare reimbursement. Strategies were compared using the incremental cost-effectiveness ratio (ICER), with effectiveness in quality-adjusted life years (QALYs), and evaluated with a willingness-to-pay (WTP) threshold of $100 000 per QALY gained. RESULTS: In the base case analysis, no treatment strategy was cost-effective at a WTP threshold. The most cost-effective therapy was SBRT alone with $150 866 per QALY gained. If median survival of SBRT alone was ≥11 months, SBRT was considered to be cost-effective. CONCLUSION: None of the treatment strategies were cost-effective. However, SBRT-based reirradiation has potential to be cost-effective.
引用
- Kim H, Vargo JA, Beriwal S, et al. Cost-effectiveness analysis of salvage therapies in locoregional previously irradiated head and neck cancer. Head Neck. 2018. PMID: 29537684. doi:10.1002/hed.25142
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。